Outcomes in patients with nontriple antiphospholipid syndrome (APS) anticoagulated with rivaroxaban

被引：1
|
作者：
Htut, Thura Win [1 ]
Milne, Denis [1 ]
Khan, Mohammed M. [1 ]
Watson, Henry G. [1 ]
机构：
[1] Aberdeen Royal Infirm, Dept Haematol, Foresterhill Hlth Campus, Aberdeen, Scotland
来源：
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2021年 / 43卷 / 05期
关键词：
anticoagulation; antiphospholipid syndrome; rivaroxaban; venous thromboembolism; warfarin; THROMBOSIS; WARFARIN;
D O I：
10.1111/ijlh.13464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E252 / E253
页数：2
相关论文
共 50 条
  • [1] Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome
    Arachchillage, D. R. J.
    Mackie, I. J.
    Efthymiou, M.
    Isenberg, D. A.
    Machin, S. J.
    Cohen, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (07) : 1264 - 1273
  • [2] Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases
    Flavio Signorelli
    Felipe Nogueira
    Vinicius Domingues
    Henrique Ataide Mariz
    Roger A. Levy
    Clinical Rheumatology, 2016, 35 : 801 - 805
  • [3] Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases
    Signorelli, Flavio
    Nogueira, Felipe
    Domingues, Vinicius
    Mariz, Henrique Ataide
    Levy, Roger A.
    CLINICAL RHEUMATOLOGY, 2016, 35 (03) : 801 - 805
  • [4] Diagnosis of the antiphospholipid syndrome in anticoagulated patients
    Mohren M.
    Daikeler T.
    Engel A.
    Guenaydin I.
    Koetter I.
    Zeitschrift für Rheumatologie, 2004, 63 (6) : 490 - 494
  • [5] Diagnosis of the antiphospholipid syndrome in anticoagulated patients
    Mohren, M
    Daikeler, T
    Engel, A
    Guenaydin, I
    Koetter, I
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2004, 63 (06): : 490 - 494
  • [6] Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
    Cohen, H.
    Dore, C. J.
    Clawson, S.
    Hunt, B. J.
    Isenberg, D.
    Khamashta, M.
    Muirhead, N.
    LUPUS, 2015, 24 (10) : 1087 - 1094
  • [7] Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism
    Arachchillage, D. R. J.
    Mackie, I. J.
    Efthymiou, M.
    Chitolie, A.
    Hunt, B. J.
    Isenberg, D. A.
    Khamashta, M.
    Machin, S. J.
    Cohen, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (11) : 2177 - 2186
  • [8] Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients
    Tripodi, Armando
    Scalambrino, Erica
    Clerici, Marigrazia
    Peyvandi, Flora
    BIOMEDICINES, 2023, 11 (06)
  • [9] Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial
    Mittal, Prabal
    Gafoor, Rafael
    Sayar, Zara
    Efthymiou, Maria
    Tohidi-Esfahani, Ibrahim
    Appiah-Cubi, Stella
    Arachchillage, Deepa J.
    Atkinson, David
    Bordea, Ekaterina
    Cardoso, M. Jorge
    Caverly, Emilia
    Chandratheva, Arvind
    Chau, Marisa
    Freemantle, Nick
    Gates, Carolyn
    Jager, H. Rolf
    Kaul, Arvind
    Mitchell, Chris
    Nguyen, Hanh
    Packham, Bunis
    Paskell, Jaye
    Patel, Jignesh P.
    Round, Chris
    Sanna, Giovanni
    Zaidi, Abbas
    Werring, David J.
    Isenberg, David
    Cohen, Hannah
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (05)
  • [10] Catastrophic antiphospholipid syndrome following the introduction of rivaroxaban
    Stammler, Romain
    Legendre, Paul
    Cacoub, Patrice
    Blanche, Philippe
    Piette, Jean-Charles
    Costedoat-Chalumeau, Nathalie
    LUPUS, 2020, 29 (07) : 787 - 790
12345